News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
About the Author - Mark Terry

BioSpace News - By Mark Terry
2 Biotechs Face Potential Catalysts as Early as Next Week 10/27/2016
Why Biogen (BIIB)'s Fate May Depend on Eli Lilly (LLY)'s Alzheimer's Data 10/27/2016
Humana (HUM) to Cover Sarepta (SRPT)'s Controversial DMD Drug But There's a Catch 10/27/2016
Biogen (BIIB)'s CEO Hunt Holds Company in Limbo 10/27/2016
Biogen (BIIB) Quietly Kills Autoimmune Program 10/26/2016
10 Possible Biotech Acquisition Targets to Keep an Eye On 10/26/2016
Meet the Cancer Scientist Leading Genentech (RHHBY)'s First Podcast 10/26/2016
Merck & Co. (MRK) and Novartis AG (NVS) CEOs Blueprint What's on Their M&A Wish List for 2017 10/26/2016
Study Stopped Early as Merck & Co. (MRK)'s Immunotherapy Drug Wows in Bladder Cancer Trial 10/26/2016
3 Promising Biotech Stocks for About $5 Bucks 10/26/2016
Here Are 4 Biotech Stocks That Are Currently Undervalued 10/26/2016
2 Biotech Stocks Under $10 to Snap Up Right Now 10/26/2016
What You Should Know About Talent Recruitment Cycles in Biopharma 10/26/2016
Johnson & Johnson (JNJ) to Stop Using Live Animals in Sale Rep Training 10/25/2016
Shire (SHPG) Pays CTI BioPharma $10.3 Million to Terminate Cancer Deal it Picked Up From Baxalta (BXLT) 10/25/2016
FDA Slaps Partial Hold on Bay Area Firm Aduro Biotech (ADRO)'s Cancer Vaccine Trial 10/25/2016
4 Biotech Stocks on the Brink of a Major Breakthrough 10/25/2016
Sarepta (SRPT) Gets No Love From the FDA's New Drugs Director 10/21/2016
Meet the $200 Million Startup That Unwinds a Woman's Biological Clock; Dr. Oz Joins Board 10/21/2016
Paying it Forward: SoCal’s Phenomenex CEO Gives $16,000 to Each Employee 10/21/2016
2 Biotechs Face Key Decisions in Mid-Fourth Quarter 10/21/2016
295 Sumitomo Dainippon Pharma Employees Take Early Retirement 10/21/2016
Gilead (GILD)'s Lack of Short-Term Razzle-Dazzle Could Topple Leadership 10/21/2016
Bay Area's BlackThorn Therapeutics Comes Out of Stealth Mode With $40 Million to Push New Neuroscience Drugs Into Trials 10/20/2016
Turns Out Gilead (GILD) May Have Wanted Tobira (TBRA) Too 10/20/2016
What You May Have Missed: Critics Point to Problems With Celgene (CELG)’s Crohn’s Drug Trial Design 10/20/2016
AbbVie (ABBV) Abandons Arthritis Pact With Ablynx (ABLYF) 10/20/2016
Daiichi Sankyo and Plexxikon Suspend Phase III Trial of Drug for Rare Tendon Cancer 10/19/2016
Pfizer (PFE) Expansion Has $2.2 Billion Economic Impact, Could Mean 5,680 Jobs in Michigan 10/19/2016
Merck & Co. (MRK)'s CMV Drug Passes Clinical Endpoints in Phase III Trial 10/19/2016
How Pfizer (PFE) is Quietly Rebuilding Its Alzheimer's Pipeline 10/19/2016
Tiny Bay Area Biotech True North Therapeutics Bags $45 Million, Bringing the Total to $142 Million 10/18/2016
FDA Panel Expresses Concerns Over Allergan (AGN)-Serenity Drug for Nighttime Urination 10/18/2016
Comeback Kid Exelixis (EXEL) Could Pose a Huge Threat to Biotech Giants Bristol-Myers Squibb (BMY) and Pfizer (PFE) 10/18/2016
Backed by Sanofi (SNY) and Others, Science 37 Secures $31 Million to Bring Clinical Trials to the Home 10/18/2016
Newest WikiLeaks Dump of Clinton Emails Exposes Some Biopharma Chatter 10/18/2016
Swinging at Wild Pitches, BioMarin (BMRN) Considering Appealing DMD Drug Rejection 10/17/2016
Share Sale Speculation: Baker Brothers Hedge Fund Registers 44 Million Shares of Seattle Genetics (SGEN) 10/14/2016
TG Therapeutics, Inc. (MHA) Stock Plunges as Company Modifies Phase III Cancer Trial Protocols 10/14/2016
7 of Top 100 CEOs Worldwide are Biopharma Executives 10/14/2016
If You Had to Choose, bluebird bio (BLUE) vs. Inovio Pharma (INO) 10/14/2016
3 Biotechs Expecting News this Week That Can Affect Their Stocks 10/14/2016
3 Healthcare Giants Are All Trying to Take a Bite Out of AbbVie (ABBV)'s Humira Domination 10/14/2016
As Pfizer (PFE) Stock Trends Downward, Investors Try to Determine Company Strategy 10/13/2016
Genzada to Build New HQ and Readies for Hiring Binge 10/13/2016
Survey Says... Gilead (GILD) Should Buy This Company 10/13/2016
ESMO 2016 Takeaways: Don't Miss Celldex (CLDX), Exelixis (EXEL) and Tesaro (TSRO) 10/13/2016
Why Incyte (INCY), Biogen (BIIB) and BioMarin (BMRN) are Hot Acquisition Targets 10/13/2016
What You Don't Know About Biotechs and Their Compassionate Use Program 10/12/2016
4 Biotech IPOs that Have Performed the Worst This Year 10/12/2016
Bay Area Biotech Startup Zymergen Just Nabbed $130 Million, and the Company Has a Robot Workforce 10/12/2016
Tiny Crescendo Biologics Hammers Out $790 Million Immuno-Oncology Deal With Biotech Giant Takeda (TKPYY) 10/11/2016
Bay Area Exelixis (EXEL)' Cabometyx Beats the Pants Off Pfizer (PFE)'s Sutent in Mid-Stage Kidney Cancer Study 10/11/2016
Amgen (AMGN) Rumored to be Quietly Rehiring Employees for Its Shuttered Colorado Facility 10/11/2016
A Tale of 2 High-Profile SoCal Biotechs That Could Disappear by 2018 10/11/2016
Industry vs. Academia: Which is the Better Place to Work as a Life Scientist 10/11/2016
Medivir (MVRBF) Slashes Jobs in Reorg, Company to Exclusively Focus on Oncology 10/10/2016
The Ripple Effect of Alnylam (ALNY)'s Blow-up Yesterday 10/10/2016
Clovis Oncology (CLVS) Stock Hammered After Revealing Mixed Results for Rucaparib 10/10/2016
Alnylam (ALNY) Stock Craters After Deaths Cause Clinical Trial to End 10/7/2016
Wanted: Pfizer (PFE) Seeks Shiny, New Headquarters in the Big Apple 10/7/2016
A Look at Gilead (GILD)'s Price Tag and Who May be Interested in Buying 10/7/2016
Top 5 Best U.S. Cities for Life Science Research Associate Jobs 10/7/2016
This Experimental Drug Could be Johnson & Johnson (JNJ)'s Next Blockbuster 10/7/2016
After Cutting Hundreds of Hospira-Related Jobs, Pfizer (PFE) Sells Hospira Infusion Systems Biz in in $1 Billion Deal 10/6/2016
Anthrax Vaccine Maker Emergent BioSolutions (EBS) Lays Off 91 in Michigan 10/6/2016
Seattle Genetics (SGEN) Adds 100,000 Square Feet to HQ, Plans to Hire 100 New Staff Every Year 10/6/2016
Deaths Lead Boehringer Ingelheim to Cancel $730 Million Cancer Deal With Hanmi Pharma (128940.KS), Hanmi Stock Tanks 10/6/2016
Editas Medicine (EDIT) Brings on New Execs From Sanofi Genzyme (SNY), Novartis AG (NVS), Baxalta (BXLT) and Bristol-Myers Squibb (BMY) 10/5/2016
A Closer Look at the Pipelines Pfizer (PFE) Inherited From Recent Acquisitions 10/5/2016
Eli Lilly (LLY) Seals $885 Million Deal for Boehringer Ingelheim's Animal Vaccine Biz 10/5/2016
10 Biotech Stocks to Watch in Q4 10/5/2016
Biotech Giant Amgen (AMGN) Forges $410 Million R&D Pact With Tiny Nuevolution 10/5/2016
Genentech (RHHBY)’s Lung Cancer Drug Alecensa Gets 2nd FDA Breakthrough Status 10/5/2016
New Startup Carrick Therapeutics Launches With $95 Million and Taps Former AstraZeneca PLC (AZN)-Eli Lilly (LLY) Exec as CEO 10/4/2016
AstraZeneca PLC (AZN) Passes Off Another Amgen (AMGN)-Partnered Drug Candidate in $1.5 Billion Deal With Allergan (AGN) 10/4/2016
Gilead (GILD) Might Avoid Fighting Celgene (CELG), But Allergan (AGN), Intercept Pharma (ICPT) and Novartis AG (NVS) Await 10/4/2016
With Biotech Stocks in a Slump, Here are 3 That Are Ready to Rock in October 10/4/2016
Sarepta (SRPT) Goes for a New DMD Combo With New $562 Million+ Deal With Summit Therapeutics 10/4/2016
Serial Biotech Bestie Celgene (CELG) Takes Out Swiss Biotech EngMab for $600 Million 10/3/2016
Struggling ImmunoGen (IMGN) Eliminates 17% of Workforce After Strategic Review 10/3/2016
Helmed by 29-Year-Old CEO, Boston's SQZ Biotech (Pronounced “Squeeze”) Nabs $16 Million and Hires Former Novartis AG (NVS) CAR-T Exec as CBO 10/3/2016
Massachusetts's Alnylam (ALNY) Falls After Stopping Development of RNAi Liver Disease Candidate ALN-AAT 10/3/2016
Pfizer (PFE) on Track to Have 3 Blockbuster Cancer Drugs 10/3/2016
Novo Nordisk A/S (NVO) Aims an Ax at R&D and HQ Staff Functions, Will Cut Up to 1,000 Jobs 9/30/2016
Next in a String of Deals, Korea’s Hanmi Pharma (128940.KS) Inks $910M Deal with Genentech (RHHBY) 9/30/2016
With a History of Political Corruption, Rock Creek Pharma Files for Bankruptcy 9/29/2016
Amgen (AMGN) Waves Golden Tickets at Biotech Startups for Kendall Square Space 9/29/2016
Pfizer (PFE)'s Newest Immunotherapy Deal Could Propel This Tiny Biotech to New Heights 9/29/2016
AstraZeneca PLC (AZN) Consolidating 350 California Jobs to the Bay Area 9/29/2016
Gilead (GILD) Can’t Buy Belgium’s Galapagos (GLPG.BR)—Yet 9/29/2016
3 Biotechs With Key Decisions Pending in the Next 18 Months 9/28/2016
Meet the Rock Star Scientist Who's Spending Facebook's CEO and Wife's $3 Billion 9/27/2016
Shire (SHPG) Terminates a Couple of Biosimilar Deals Made by Baxalta (BXLT) 9/27/2016
A Look at What's Next for Pfizer (PFE), More Acquisitions Could Come 9/27/2016
Cancer Immunotherapy Startup Fortis Therapeutics Launches With $18 Million Series A 9/27/2016
Two Promising Biotech Stocks Under $5, and One to Avoid Like the Plague 9/27/2016
New Setback Increases Sanofi (SNY)'s Hunger for a M&A 9/27/2016
It’s Official! No Divorce for Pfizer (PFE)'s Two Units 9/26/2016
PerkinElmer (PKI) Reorganizes and Splits Into Two Business Segments 9/26/2016
Speculation Mounts Over an Allergan (AGN)-Gilead (GILD) Mega Deal 9/26/2016
Biotech vs. Big Pharma: Which is the Better Place to Work? 9/26/2016
Saga Continues for Sarepta (SRPT) as FDA Head Calls for Retraction of 'Misleading' 2013 Study 9/23/2016
This Biotech Has the Upper Hand Over Allergan (AGN) and Gilead (GILD) in the Heated Nash Battle 9/23/2016
This Little Biotech Could be a New Acquisition Target for Allergan (AGN) and Biogen (BIIB) 9/23/2016
Investors Beware: Thin CAR-T Data Could Make or Break Juno (JUNO) and Kite Pharma (KITE) 9/23/2016
AstraZeneca PLC (AZN) to Shutter Pennsylvania Office, 134 Employees Affected 9/23/2016
Genentech (RHHBY) Gambles $310 Million+ on German Biotech BioNTech's mRNA Cancer Vaccine Tech 9/23/2016
Facebook CEO Zuckerberg and Wife Chan Set Up New Bay Area Biohub With $3 Billion Investment to Cure All Diseases 9/23/2016
4 Biotechs Gilead (GILD) Could Be Targeting After Losing Medivation (MDVN) 9/22/2016
Bayer (BAY)’s Dermatology Unit Sale Said to Attract Teva (TEVA) and Perrigo (PRGO) 9/22/2016
The Power of Three: Sarepta (SRPT) to Open New Plant, Hire Staff and Confirms Kaye as CEO 9/21/2016
Iroko Pharma Slashes a Quarter of Workforce, But Plans to Hire 90 Sales Reps 9/21/2016
Meet the Powerful Woman Behind the Scenes of Sarepta (SRPT)'s DMD Drug Approval 9/21/2016
Continuing Its String of Deals, Allergan (AGN) Buys Bay Area’s Tobira (TBRA) for $1.695 Billion 9/21/2016
Victory at Last! Sarepta (SRPT) Stock Doubles as the FDA Finally Approves DMD Drug 9/20/2016
Everybody's Talkin' About New Houston Biotech Startup Cellenkos 9/20/2016
The Drugmaker That Could Knock Gilead (GILD) Off Its HIV Throne 9/20/2016
How Ionis Pharma (IONS) is Beating the Pants Off of Competitors Like Alnylam (ALNY), Arrowhead Pharma (ARWR) and Moderna 9/20/2016
Will Biogen (BIIB)’s Alzheimer’s Drug Be a Miracle Drug or Just Another Bomb? 9/20/2016
FDA Places Clinical Hold on AML Drug Co-Developed by Johnson & Johnson (JNJ) and Genmab A/S (GEN.CO) 9/20/2016
M&A Bonanza Continues as Johnson & Johnson (JNJ) Pays $4.325 Billion for Abbott (ABT)'s Eye Surgery Biz 9/19/2016
4 Precious Cannabis-Based Biotechs are Potential Takeover Targets 9/19/2016
Pfizer (PFE) May No Longer Need to Split Post-Medivation (MDVN) 9/19/2016
Eisai Company (ESALY.PK) Launches Ambitious 90-Scientist Collaborative R&D Unit in Boston Area 9/16/2016
SoCal's Aerie (AERI) Stock Soars Over the Rainbow on Positive Phase III Eye Drug Data 9/16/2016
What's PARP? Meet Two of Biotech's Newest M&A Targets: Tesaro (TSRO) and Clovis Oncology (CLVS) 9/16/2016
Gilead (GILD) to Release Data on 9 Clinical Trials Before End of the Year 9/16/2016
Bay Area's Rigel (RIGL) Slashes 38% of Workforce; Shifts From R&D to Commercial Operation 9/16/2016
Bay Area Depomed (DEPO) Rumored to be Putting Itself Up for Sale (Once Again) 9/16/2016
Regeneron (REGN) Plans to Double R&D Space With 1 Million Square Feet of Additions 9/15/2016
Let's Hear It for the Yale Professor Who Launched New Biotech Kleo 9/15/2016
Born to Be Wild: Relay Therapeutics Launches With $57 Million to Make Movies of Cell Proteins 9/15/2016
Why Gilead (GILD) Should Think About Wooing Massachusetts' Tesaro (TSRO) 9/15/2016
Turn the Page: Sarepta (SRPT) Stock Pops on Rumors DMD Drug Naysayer Leaves the FDA 9/15/2016
With R&D Ops in the Bay Area, Cambridge Startup Delinia Launches With $35 Million and Plans to Start Hiring 9/14/2016
These are the Days of Moderna's Lives: Behind the Curtain of One of the Most Mysterious Biotechs 9/14/2016
The 3 Most-Coveted Cancer Acquisition Targets Post-Medivation (MDVN) 9/14/2016
Never Say Never: Why Gilead (GILD) Could be a Takeover Target 9/14/2016
Everything's Bigger in Texas: Aeglea (AGLE) Quickly Growing into Leading Austin Biotech 9/14/2016
There's No Place Like Massachusetts for China's Largest Biotech Vcanbio 9/14/2016
Will FDA’s Scrutiny of Pfizer (PFE)’s Chantix Trial Go Up in Smoke? 9/13/2016
Alphabet's Verily, Sanofi (SNY) Launch $500 Million Onduo, Joint Venture to Open New HQ in Kendall Square 9/13/2016
10 Biotechs—Count ‘Em, 10!—With Big Decisions in the Fourth Quarter 9/13/2016
Cha-Ching...5 Boston Area Companies That Cashed in Big This Week 9/12/2016
Home Sweet Home: 11 Biotech Startups Land New Digs at Harvard Life Lab 9/12/2016
Gene Editing Phenom CRISPR (CRSP) Files for $90 Million IPO 9/12/2016
Why People Are Angry at This Wells Fargo Ad About Scientists 9/9/2016
Meet the Next Wave of Scientists Who Are Taking Over Biotech 9/9/2016
Investors: Here's What You Need to Know About Gilead (GILD) and Roche (RHHBY) 9/9/2016
Ooh...Pfizer (PFE) Did it Again, Ties It Up With a Startup and Spinout 9/9/2016
Bay Area's Catalyst Biosciences Halves Workforce to Focus on Clinical Hemostasis Programs 9/8/2016
With $1.4 Billion in Cash, Booming Moderna Plans to Hire 100 and Drops $100 Million on New Manufacturing Facility 9/8/2016
GW Pharma (GWPH) Stock Pops on Buyout Chatter 9/8/2016
Taking a Look at 3 Stocks That are Better Buys Than Gilead (GILD) 9/8/2016
Another Celgene (CELG) Bet Pays Off as Agios (AGIO) Eyes Early Approval of Leukemia Drug 9/8/2016
Is Biogen (BIIB) Even Buyout Worthy? 9/7/2016
Cancer Drug Developed by Eliza Hall Institute, AbbVie (ABBV) and Genentech (RHHBY) “Melts Away Cancer” 9/7/2016
Investors Wait Patiently for Gilead (GILD) and Its CEO to Make a M&A for Growth and to Get Out of Share Slump 9/7/2016
NeuroPhage Transforms Into Proclara, Bags $47 Million and and Launches Phase Ib Alzheimer’s Trial 9/7/2016
SEC Filings Show How Medivation (MDVN)’s CEO and Board Backroom Dealings Drove Up Acquisition Price 9/7/2016
Falcon Genomics Bankruptcy Underlines Pittsburgh Venture Capital Weakness 9/7/2016
How the Bay Area is Still King of Biotech 9/7/2016
September is a Busy Month for 7 Biotechs 9/6/2016
Aduro Biotech (ADRO) Opens New HQ in the Bay Area, Eventually to House 400 Workers 9/6/2016
Genentech (RHHBY)'s Tecentriq Shows Positive Data in Phase III Trial, Has an Upcoming Action Date in October 9/2/2016
Arena (ARNA) Forms Drug Discovery Incubator Beacon Discovery 9/2/2016
Why Cytokinetics (CYTK) Stock Dropped on the Good News of an Upcoming Phase III Trial 9/2/2016
Layoffs are Underway as Teva (TEVA) Winds Down Operations at New York Plant 9/2/2016
3 Biotechs Expecting to Release Clinical Trial Data Soon 9/1/2016
SEC Docs Say Pfizer (PFE) Beat Out 4 Companies to Buy Medivation (MDVN) 9/1/2016
Among Global Challenges, Novo Nordisk A/S (NVO)’s CEO Steps Down, Executive Team is Shuffled 9/1/2016
Athenex Looking Elsewhere as State Lags on Plans for Cancer Drug Plant 8/31/2016
Key Parkinson's Trial Delayed Due to Feud Between a Georgetown University Scientist and The Michael J. Fox Foundation 8/31/2016
3 Potential Juicy Biotech Acquisition Targets 8/31/2016
2 High-Risk Biotechs Ready to Rock—Maybe 8/31/2016
CRO AMRI (AMRI) Restructures and Cuts Jobs as Result of Euticals Acquisition 8/31/2016
Stock Pops as Medivir (MVRBF) Decides to Split into Two Companies 8/31/2016
What You Don't Know: Pfizer (PFE)’s Connection to Mylan (MYL) and EpiPen 8/31/2016
Why 3 Billionaires Ditched Johnson & Johnson (JNJ) Stock 8/30/2016
Biotechs are Expanding in the Bay Area Again: Bristol-Myers Squibb (BMY), Genentech (RHHBY), Gilead (GILD), Illumina (ILMN) and Verily and More 8/30/2016
AstraZeneca PLC (AZN) Puts 'For Sale' Sign on U.S. HQ 8/29/2016
AxoSim Leads a Biotech Startup Scene in New Orleans 8/29/2016
Mylan (MYL) Isn't Alone: 11 Drug Companies With Muscular Pricing Power and Staggering Profit Margins 8/26/2016
Embattled Theranos Plans to Appeal to Re-Open Its Lab in Newark, California 8/26/2016
Amidst Dramatic Reorganization, Takeda (TKPYY) May (Or May Not) Shutter Cambridge, UK Site 8/26/2016
How Pfizer (PFE)’s Antibiotics Buy from AstraZeneca PLC (AZN) Will Affect Jobs in the U.S. 8/26/2016
Led by Former Genentech (RHHBY) Execs, Denali Banks $130 Million, Initiates Trial and Announces a Handful of Partnerships 8/26/2016
Just Days after a $14 Billion Medivation (MDVN) Buy, Pfizer (PFE) Buys AstraZeneca PLC (AZN)'s Antibiotics Business for $1.5 Billion-Plus 8/26/2016
Medivation (MDVN) Exec Jumps Ship to Become CMO at BeiGene (BGNE) 8/26/2016
Amgen (AMGN) Remains Hush-Hush Over FDA Rejection of Parsabiv 8/25/2016
These Biotech Employers Hired the Most New Grads In Life Sciences 8/25/2016
3 High-Risk, High-Reward Biotech Stocks 8/25/2016
Bay Area's AllCells to Open Up Shop in Boston 8/24/2016
Celgene (CELG)'s Once-Nightmare Drug Turned Blockbuster Returns 8/24/2016
Affiliate of Amethyst Tech, Advent Laboratories, to Move to Western Maryland and Create 20 Jobs 8/24/2016
6 Hot Biotech Acquisition Targets 8/23/2016
SoCal's Sophiris Bio (SPHS) Evaluating Options, Will Not Pursue New Clinical Trials Unless New Financing is Obtained 8/23/2016
A Look at the Winners and Losers of Medivation (MDVN)'s $14 Billion Pfizer (PFE) Buyout Deal 8/23/2016
Pfizer (PFE) Scoops Sanofi (SNY) With $14 Billion Buyout Deal for Medivation (MDVN) 8/23/2016